Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD

Respiration

Volumn 71, Issue 2, 2004, Pages 159-164

  Cazzola, Mario ^a,f   Matera, Maria Gabriella ^b   Ruggeri, Paolo ^c   Sanduzzi, Alessandro ^d   Spicuzza, Lucia ^e   Vatrella, Alessandro ^d   Girbino, Giuseppe ^c  

^a CARDARELLI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e UNIVERSITY OF CATANIA   (Italy)

^f NONE   (Italy)

Author keywords

Arterial hypertension; Chronic obstructive pulmonary disease; Nebivolol; Nifedipine; Salbutamol

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; NEBIVOLOL; NIFEDIPINE; PLACEBO; SALBUTAMOL;

ADULT; AGED; AIRWAY OBSTRUCTION; ANTIHYPERTENSIVE THERAPY; BETA ADRENERGIC RECEPTOR BLOCKING; BRONCHODILATATION; CARDIOVASCULAR EFFECT; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TRANSPORT; FEMALE; GASTROINTESTINAL TRANSIT; HEART RATE VARIABILITY; HUMAN; HYPERTENSION; INHALER; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; SCORING SYSTEM; SHORT COURSE THERAPY; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; SPIROMETRY; STATISTICAL SIGNIFICANCE; SYMPTOMATOLOGY;

AGED; ALBUTEROL; ANTIHYPERTENSIVE AGENTS; BENZOPYRANS; BLOOD PRESSURE; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NIFEDIPINE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TREATMENT OUTCOME; VASODILATOR AGENTS; VITAL CAPACITY;

EID: 1942499632     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076677     Document Type: Review

References (30)

1. Antonelli Incalzi R, Fuso L, De Rosa M, et al: Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-2800.
2. Meier JL, Lopez J, Siegel D: Prevalence and treatment of hypertension complicated by comorbid conditions. J Clin Hypertens (Greenwich) 1999;1:209-211.
3. Dart RA, Gollub S, Lazar J, et al: Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest 2003;123:222-243.
4. Chafin CC, Soberman JE, Demirkan K, et al: β-Blockers after myocardial infarction: Do benefits ever outweigh risks in asthma? Cardiology 1999;92:99-105.
5. Wellstein A, Palm D, Belz G, et al: Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to β-adrenoceptor occupancy. Eur Heart J 1987;8(suppl M): 3-8.
6. Cazzola M, Noschese P, D'Amato G, et al: The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest 2002;121:230-241.
7. Mangrella M, Rossi F, Fici F, et al: Pharmacology of nebivolol. Pharmacol Res 1998;38:419-431.
8. Mohammed AF, Hulks G, Thomson NC, et al: Effects of nebivolol, atenolol and propranolol on airway β-adrenergic responsiveness in normal subject. Drug Investig 1991;3(suppl 1): 196-198.
9. Cazzola M, Noschese P, D'Amato M, et al: Comparison of the effects of single oral doses of nebivolol and celiprolol on airways in patients with mild asthma. Chest 2000;118:1322-1326.
10. Van Bortel LM, de Hoon JN, Kool MJ, et al: Pharmacological properties of nebivolol in man. Eur J Clin Pharmacol 1997;51:379-384.
11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO workshop report. Bethesda, National Heart, Lung and Blood Institute, April 2001; Update of the Management Sections, GOLD website (www.goldcopd.com). Date updated: July 2003.
12. Lammers JW, Folgering HT, van Herwaarden CL: Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. Br J Clin Pharmacol 1985;20:205-210.
13. Salpeter SS, Ormiston T, Salpeter E, et al: Cardioselective β-blockers for chronic obstructive pulmonary disease (Cochrane Review). Cochrane Database Syst Rev 2002;2:CD003566.
14. Chester EH, Schwartz HJ, Fleming GM: Adverse effect of propranolol on airway function in nonasthmatic chronic obstructive lung disease. Chest 1981;79:540-544.
15. Ranchod A, Keeton GR, Benatar SR: The effect of beta-blockers on ventilatory function in chronic bronchitis. S Afr Med J 1982;61:423-424.
16. Fenster PE, Hasan FM, Abraham T, et al: Effect of metoprolol on cardiac and pulmonary function in chronic obstructive pulmonary disease. Clin Cardiol 1983;6:125-129.
17. Dorow P, Bethge H, Tonnesmann U: Effects of single oral doses of bisoprolol and atenolol on airway function in nonasthmatic chronic obstructive lung disease and angina pectoris. Eur J Clin Pharmacol 1986;31:143-147.
18. Fogari R, Zoppi A, Tettamanti F, et al: Comparative effects of celiprolol, propranolol, oxprenolol, and atenolol on respiratory function in hypertensive patients with chronic obstructive lung disease. Cardiovasc Drugs Ther 1990;4:1145-1149.
19. Salpeter SR, Ormiston TM, Salpeter EE: Cardioselective β-blockers in patients with reactive airway disease: A meta-analysis. Ann Intern Med 2002;137:715-725.
20. 2-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-684.
21. Goldie RG, Paterson JW, Lulich KM: Adrenoceptors in airway smooth muscle. Pharmacol Ther 1990;48:295-322.
22. Ikeda H, Takahashi K, Sasaki H, et al: Acute effects of nifedipine on patients with chronic obstructive lung disease. Arzneimittelforschung 1985;35:518-521.
23. van Herwaarden CL: β-Adrenoceptor blockade and pulmonary function in patients suffering from chronic obstructive lung disease. J Cardiovasc Pharmacol 1983;5(suppl):S46-S50.
24. Matera MG: Nitric oxide and airways. Pulm Pharmacol Ther 1998;11:341-348.
25. Dal Negro RW, Tognella S, Pomari C: Once-daily nebivolol 5 mg does not reduce airway patency in patients with chronic obstructive pulmonary disease and arterial hypertension. Clin Drug Invest 2002;22:361-367.
26. Clini E, Bianchi L, Pagani M, et al: Endogenous nitric oxide in patients with stable COPD: Correlates with severity of disease. Thorax 1998;53:881-883.
27. 2-adrenergic receptor-mediated nitric oxide production. Circulation 2000;102:677-684.
28. Kakoki M, Hirata Y, Hayakawa H, et al: Effects of vasodilatory β-adrenoceptor antagonists on endothelium-derived nitric oxide release in rat kidney. Hypertension 1999;33:467-471.
29. 2-adrenoceptors. J Appl Physiol 1988;65:700-705.
30. Cazzola M, Matera MG: 5-HT modifiers as a potential treatment of asthma. Trends Pharmacol Sci 2000;21:13-16.